Advertisement

Topics

Keytruda combo fails at Phase 3 in metastatic melanoma

04:37 EDT 9 Apr 2018 | Pharmafile

Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results of a Phase 3 study had revealed that its IDO1 inhibitor epacadostat, when applied in combination with MSD’s Keytruda (pembrolizumab), failed to meet its primary endpoint of improving progression-free survival (PFS) in patients with unresectable or metastatic melanoma compared to Keytruda alone.

read more

Original Article: Keytruda combo fails at Phase 3 in metastatic melanoma

NEXT ARTICLE

More From BioPortfolio on "Keytruda combo fails at Phase 3 in metastatic melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...